Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

A new immune signature for survival prediction and immune checkpoint molecules in lung adenocarcinoma.

Journal of translational medicine - 6 Mar 2020

Guo Dina, Wang Mian, Shen Zhihong, Zhu Jiaona

Abstract excerpt

BACKGROUND: Lung adenocarcinoma (LUAD) is the most frequent subtype of lung cancer. The prognostic signature could be reliable to stratify LUAD patients according to risk, which helps the management of the systematic treatments. In this study, a systematic and reliable immune signature was performed to estimate the prognostic stratification in LUAD. METHODS: The profiles of immune-related genes for patients with...

Topics

Adenocarcinoma of Lung
Humans
Immune Checkpoint Proteins
Lung Neoplasms
Mutation
Prognosis

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 32143735
DOI: 10.1186/s12967-020-02286-z
PMCID: PMC7060601

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A new immune signature for survival prediction and immune checkpoint molecules in lung adenocarcinoma.PMID 32143735Read ↗

Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinomaSemantic proximity Read ↗

Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma.Semantic proximity Read ↗

An immune gene signature to predict prognosis and immunotherapeutic response in lung adenocarcinomaSemantic proximity Read ↗

An Immune Gene Signature for Prediction of Overall Survival and Response to Immune Checkpoint Inhibitors Therapy in Patients with Lung AdenocarcinomaSemantic proximity Read ↗

Systematic construction and validation of an immune prognostic model for lung adenocarcinomaSemantic proximity Read ↗

Individualized Prognostic Score for Lung Adenocarcinoma Based on Immune StatusSemantic proximity Read ↗

Establishment and validation of an immune-associated signature in lung adenocarcinoma.Semantic proximity Read ↗

Identification and validation of immune-related lncRNA prognostic signature for lung cancerSemantic proximity Read ↗

Identification of an immune-related genes signature in lung adenocarcinoma to predict survival and response to immune checkpoint inhibitors.Semantic proximity Read ↗

Identification of lung adenocarcinoma subtypes and predictive signature for prognosis, immune features, and immunotherapy based on immune checkpoint genesSemantic proximity Read ↗

Construction of a Prognostic Immune Signature for Squamous-Cell Lung Cancer to Predict Survival.Semantic proximity Read ↗

Analysis of Clinical Implications and Immune Landscape in Prognostic Model based on Immune Cell Signatures for Lung Adenocarcinoma PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.